Quarterly report pursuant to Section 13 or 15(d)

Net Loss Per Share

v3.19.1
Net Loss Per Share
3 Months Ended
Mar. 31, 2019
Earnings Per Share [Abstract]  
Net Loss Per Share

11. Net Loss Per Share


Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the periods. Fully diluted net loss per common share is computed using the weighted average number of common and dilutive common equivalent shares outstanding during the periods. Common equivalent shares consist of stock options and warrants that are computed using the treasury stock method.


For the three months ended March 31, 2019 and 2018, all of the Company’s common stock options, unvested restricted stock units and warrants were anti-dilutive and therefore have been excluded from the diluted calculation.


The following table reconciles net loss to net loss attributable to Heat Biologics, Inc.:


 

 

For the three months ended

March 31,

 

 

 

2019

 

2018

 

Net loss

 

$

(5,819,081

)

$

(3,528,227

)

Net loss - Non-controlling interest

 

 

(103,605

)

 

(206,461

)

Net loss attributable to Heat Biologics, Inc.

 

$

(5,715,476

)

$

(3,321,766

)

 

 

 

 

 

 

 

  

Weighted-average number of common shares used in net loss per share attributable to common stockholders —basic and diluted

 

 

33,225,164

 

 

4,709,533

 

Net loss per share attributable to Heat Biologics, Inc —basic and diluted

 

$

(0.17

)

$

(0.71

)

 

The following potentially dilutive securities were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:


 

 

 

For the three months ended

March 31,

 

 

 

 

2019

 

2018

 

Outstanding stock options

 

 

 

3,008,754

 

 

426,393

 

Restricted stock subject to forfeiture and restricted stock units

 

 

 

838,679

 

 

63,331

 

Outstanding common stock warrants

 

 

 

9,030,730

 

 

310,397